Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 20, 2024

SELL
$7.03 - $11.07 $234,977 - $370,014
-33,425 Reduced 45.24%
40,461 $300,000
Q4 2023

Feb 26, 2024

BUY
$6.25 - $11.11 $461,787 - $820,873
73,886 New
73,886 $748,000
Q2 2023

Jul 27, 2023

BUY
$6.36 - $11.47 $212,137 - $382,581
33,355 New
33,355 $275,000
Q3 2022

Nov 07, 2022

SELL
$12.16 - $19.42 $9,205 - $14,700
-757 Reduced 2.38%
31,055 $380,000
Q2 2022

Aug 09, 2022

BUY
$9.99 - $21.35 $317,801 - $679,186
31,812 New
31,812 $376,000
Q4 2021

Feb 17, 2022

SELL
$26.55 - $40.57 $1.36 Million - $2.08 Million
-51,160 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$39.27 - $72.94 $2.01 Million - $3.73 Million
51,160 New
51,160 $2.1 Million
Q2 2021

Sep 17, 2021

SELL
$31.29 - $56.64 $600,861 - $1.09 Million
-19,203 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$39.71 - $90.58 $9,689 - $22,101
244 Added 1.29%
19,203 $807,000
Q4 2020

Feb 24, 2021

BUY
$27.07 - $84.35 $27,394 - $85,362
1,012 Added 5.64%
18,959 $1.33 Million
Q3 2020

Dec 11, 2020

SELL
$28.06 - $37.16 $492,621 - $652,380
-17,556 Reduced 49.45%
17,947 $504,000
Q2 2020

Aug 07, 2020

BUY
$18.5 - $34.34 $322,547 - $598,717
17,435 Added 96.5%
35,503 $1.05 Million
Q4 2019

Feb 04, 2020

BUY
$19.49 - $32.63 $352,145 - $589,558
18,068 New
18,068 $535,000
Q1 2019

Apr 12, 2019

SELL
$19.43 - $26.41 $172,849 - $234,943
-8,896 Closed
0 $0
Q4 2018

Jan 16, 2019

SELL
$18.19 - $31.79 $10,659 - $18,628
-586 Reduced 6.18%
8,896 $202,000
Q3 2018

Nov 13, 2018

BUY
$27.65 - $38.39 $262,177 - $364,013
9,482 New
9,482 $302,000
Q2 2018

Jul 30, 2018

SELL
$31.4 - $41.01 $381,353 - $498,066
-12,145 Closed
0 $0
Q2 2018

Jul 30, 2018

SELL
$31.4 - $41.01 $163,876 - $214,031
-5,219 Reduced 30.06%
12,145 $435,000
Q1 2018

May 14, 2018

BUY
$29.84 - $44.08 $518,141 - $765,405
17,364 New
17,364 $576,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $239M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.